Distribution of patients according to the chemotherapy and radiotherapy received; cumulative doses of leukemogenic drugs contained in the chemotherapy protocols used
| . | Total . | . | |
|---|---|---|---|
| n . | % . | Cumulative chemotherapy doses . | |
| Chemotherapy received | |||
| None | 316 | 2.6 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 2× AV | 152 | 1.3 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 2× ABV | 190 | 1.6 | C: 0 mg/m2, P. 0 mg/m2, E: 0 mg/m2 |
| 2× AVD | 409 | 3.4 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 2× ABVD | 1 333 | 11.2 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 2× COPP/ABVD | 1 113 | 9.3 | C: 2 600 mg/m2, P: 2 800 mg/m2, E: 0 mg/m2 |
| 4× ABVD | 2 058 | 17.2 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 4× COPP/ABVD | 277 | 2.3 | C: 5 200 mg/m2, P: 5 600 mg/m2, E: 0 mg/m2 |
| 4× BEACOPPbaseline | 680 | 5.7 | C: 2 600 mg/m2, P: 2 800 mg/m2, E: 1 200 mg/m2 |
| 2× BEACOPPescalated + 2× ABVD | 759 | 6.4 | C: 2 500 mg/m2, P: 1 400 mg/m2, E: 1 200 mg/m2 |
| 8× BEACOPPbaseline | 483 | 4.0 | C: 5 200 mg/m2, P: 5 600 mg/m2, E: 2 400 mg/m2 |
| 6× BEACOPPescalated | 694 | 5.8 | C: 7 500 mg/m2, P: 4 200 mg/m2, E: 3 600 mg/m2 |
| 8× BEACOPP-14 | 777 | 6.5 | C: 5 200 mg/m2, P: 5 600 mg/m2, E: 2 400 mg/m2 |
| 4× BEACOPPescalated + 4× BEACOPPbaseline | 784 | 6.6 | C: 7 600 mg/m2, P: 5 600 mg/m2, E: 3 600 mg/m2 |
| 8× BEACOPPescalated | 1 927 | 16.1 | C: 10 000 mg/m2, P: 5 600 mg/m2, E: 4 800 mg/m2 |
| Total | 11 952 | 100.0 | |
| Radiotherapy received | |||
| None | 3 200 | 26.8 | |
| <EF | 7 567 | 63.3 | |
| EF | 1 185 | 9.9 | |
| Total | 11 952 | 100.0 | |
| . | Total . | . | |
|---|---|---|---|
| n . | % . | Cumulative chemotherapy doses . | |
| Chemotherapy received | |||
| None | 316 | 2.6 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 2× AV | 152 | 1.3 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 2× ABV | 190 | 1.6 | C: 0 mg/m2, P. 0 mg/m2, E: 0 mg/m2 |
| 2× AVD | 409 | 3.4 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 2× ABVD | 1 333 | 11.2 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 2× COPP/ABVD | 1 113 | 9.3 | C: 2 600 mg/m2, P: 2 800 mg/m2, E: 0 mg/m2 |
| 4× ABVD | 2 058 | 17.2 | C: 0 mg/m2, P: 0 mg/m2, E: 0 mg/m2 |
| 4× COPP/ABVD | 277 | 2.3 | C: 5 200 mg/m2, P: 5 600 mg/m2, E: 0 mg/m2 |
| 4× BEACOPPbaseline | 680 | 5.7 | C: 2 600 mg/m2, P: 2 800 mg/m2, E: 1 200 mg/m2 |
| 2× BEACOPPescalated + 2× ABVD | 759 | 6.4 | C: 2 500 mg/m2, P: 1 400 mg/m2, E: 1 200 mg/m2 |
| 8× BEACOPPbaseline | 483 | 4.0 | C: 5 200 mg/m2, P: 5 600 mg/m2, E: 2 400 mg/m2 |
| 6× BEACOPPescalated | 694 | 5.8 | C: 7 500 mg/m2, P: 4 200 mg/m2, E: 3 600 mg/m2 |
| 8× BEACOPP-14 | 777 | 6.5 | C: 5 200 mg/m2, P: 5 600 mg/m2, E: 2 400 mg/m2 |
| 4× BEACOPPescalated + 4× BEACOPPbaseline | 784 | 6.6 | C: 7 600 mg/m2, P: 5 600 mg/m2, E: 3 600 mg/m2 |
| 8× BEACOPPescalated | 1 927 | 16.1 | C: 10 000 mg/m2, P: 5 600 mg/m2, E: 4 800 mg/m2 |
| Total | 11 952 | 100.0 | |
| Radiotherapy received | |||
| None | 3 200 | 26.8 | |
| <EF | 7 567 | 63.3 | |
| EF | 1 185 | 9.9 | |
| Total | 11 952 | 100.0 | |
C, cyclophosphamide; E, etoposide; EF, extended-field; P, procarbazine.